Fragment-based drug discovery (FBDD) offers an efficient approach for researchers to access complex molecules for drug discovery. This technique involves identifying small, bioactive molecules known as fragments that bind to a specific target protein. These fragments serve as starting points for the development of larger, more potent drug candidates. FBDD uses a variety of techniques, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational methods, to identify fragments that bind to the target protein. Once identified, these fragments can be chemically modified and combined to generate larger, more complex molecules that retain the desired binding properties. This iterative process enables researchers to efficiently explore a vast chemical space and identify promising drug candidates for further development.

Key steps in fragment-based drug discovery (FBDD):

Target selection:

- Identify a disease-relevant protein target for drug discovery.

Fragment library design:

- Generate a diverse library of small, drug-like molecules, known as fragments, using combinatorial chemistry or computational methods.

Fragment screening:

- Screen the fragment library against the target protein using biophysical techniques such as X-ray crystallography or NMR spectroscopy.

Fragment hit analysis:

- Analyze the binding modes and affinities of the fragment hits to identify potential starting points for drug design.

Fragment elaboration:

- Chemically modify and combine the fragment hits to generate larger, more complex molecules that retain the desired binding properties.

Structure-activity relationship (SAR) studies:

- Perform SAR studies to optimize the potency and selectivity of the fragment-derived molecules.

Lead optimization:

- Further optimize the lead compounds through iterative rounds of design, synthesis, and testing to improve their drug-like properties.

Preclinical and clinical development:

- Evaluate the safety and efficacy of the optimized compounds in preclinical studies and advance promising candidates into clinical trials.